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Abstract
Aims: To assess three-year clinical outcome following randomised use of the second-generation Resolute 
zotarolimus-eluting stent (ZES) and the XIENCE V everolimus-eluting stent (EES). For Resolute ZES and 
randomised use, outcome data ≥3 years are relatively scarce.
Methods and results: The TWENTE trial examined 1,391 patients with stable angina or non-ST-elevation 
acute coronary syndromes, of whom 21.6% were diabetics, 70.1% had complex B2 or C lesions and 77.4% 
had “off-label” indications for DES use. Three-year follow-up data were obtained in 1,381 patients (99.3%; 
10 withdrawals). Adverse clinical events were independently adjudicated. The primary endpoint target vessel 
failure (TVF), a composite of cardiac death, target vessel-related myocardial infarction and clinically indi-
cated target vessel revascularisation, was 12.1% for Resolute ZES and 13.4% for XIENCE V EES (p=0.50). 
Cardiac death rates were 1.9% vs. 3.5% (p=0.06); the other individual components of TVF also showed no 
significant between-group differences. The rates of definite-or-probable stent thrombosis (1.4% vs. 1.6%, 
p=0.82) and very late stent thrombosis (0.6% vs. 0.4%, p=1.0) did not differ between the groups.
Conclusions: Three-year follow-up data of patients included in the randomised TWENTE trial demon-
strated similar and sustained safety and efficacy of Resolute ZES and XIENCE V EES.
KEYWORDS
• Co-Cr EES
• Co-Cr R-ZES
• coronary 
revascularisation
• everolimus-eluting 
stent(s)
• long-term outcome
• long-term result(s)
• percutaneous 
coronary 
intervention(s)
• randomised study
• second-generation 
drug-eluting 
stent(s)
• stent(s)
• stent thrombosis
• TWENTE trial
• zotarolimus-eluting 
stent(s)
SUBMITTED ON 28/02/2014 - REVISION RECEIVED ON 12/06/2014 - ACCEPTED ON 24/06/2014
1277
Safety of DES (TWENTE 3-year)
EuroIntervention 2
0
1
5
;10
:1276-1279
Introduction
Clinical follow-up data beyond two years provide valuable infor-
mation on the long-term safety of drug-eluting stents (DES). The 
Resolute zotarolimus-eluting stent (ZES) (Medtronic Inc., Santa 
Rosa, CA, USA) is a second-generation DES that is widely used, 
but only a single randomised study, the RESOLUTE All-Comers 
trial, has published outcome data beyond two years1. The ran-
domised TWENTE trial has previously demonstrated, in a broad 
study population, the non-inferiority of the Resolute ZES compared 
to the XIENCE V everolimus-eluting stent (EES) (Abbott Vascular, 
Santa Clara, CA, USA)2,3. Meanwhile, three-year outcome data of 
the TWENTE trial have been obtained, which contribute signifi-
cantly to the knowledge about the longer-term safety and efficacy 
of second-generation DES.
Methods
Study design, definitions of clinical endpoints, characteristics of 
patients, lesions, procedures and the one- and two-year clinical 
outcomes of the investigator-initiated, patient-blinded, randomised 
TWENTE trial (ClinicalTrials.gov NCT01066650) have been pre-
viously reported2,3. The TWENTE trial enrolled 1,391 patients with 
stable angina or non-ST-elevation acute coronary syndromes, of 
whom 21.6% were diabetics, 70.1% had complex lesions and 77.4% 
fulfilled at least one criterion of off-label DES use2. More than 80% 
of all eligible patients were enrolled in this randomised clinical 
trial4. Between two- and three-year follow-up, the external CRO 
Diagram (Zwolle, The Netherlands) monitored clinical outcome in 
10% of randomly selected patients and organised the adjudication 
of adverse events by an independent clinical events committee. The 
TWENTE trial and follow-up have been approved by the institu-
tional medical ethics committee, complied with the Declaration of 
Helsinki and patients provided written informed consent. Clinical 
endpoints were defined according to the Academic Research 
Consortium (ARC)5; myocardial infarction (MI) was classified 
according to the extended historical definition6. Primary endpoint 
of TWENTE was target vessel failure (TVF) at one year, a com-
posite of cardiac death, target vessel-related MI and clinically indi-
cated target vessel revascularisation (TVR). A p-value <0.05 was 
considered statistically significant and statistics were performed 
as appropriate and corresponding to previous reports2,3 using SPSS 
15.0 (SPSS Inc., Chicago, IL, USA).
Results
We obtained three-year follow-up in 1,381 patients (99.3%; i.e., all 
enrolled patients except 10 withdrawals). Both the Resolute ZES 
and the XIENCE V EES groups showed a favourable outcome with 
a similar incidence of TVF (84/692 [12.1%] vs. 92/689 [13.4%], 
plog-rank=0.58; Figure 1, Table 1), a composite of cardiac death, target 
vessel-related MI and clinically indicated TVR. Between DES groups, 
there was also no significant difference in a patient-oriented compos-
ite endpoint, consisting of all-cause death, any MI or any revascu-
larisation (120/692 [17.2%] vs. 114/689 [16.5%], p=0.69; Table 1).
In addition, as shown in Table 1 and Figure 2, the rates of very 
late definite-or-probable stent thrombosis (>12 months) were simi-
lar and low (4/692 [0.6%] vs. 3/689 [0.4%], p=1.0). During three-
year follow-up, the rates of definite stent thrombosis (7/692 [1.0%] 
vs. 2/689 [0.3%], p=0.18) and definite-or-probable stent thrombo-
sis (10/692 [1.4%] vs. 11/689 [1.6%), p=0.82) remained low and 
similar for both groups. At three-year follow-up, 5.0% (33/657) of 
patients in the Resolute ZES group and 5.9% (38/645) of patients in 
the XIENCE V EES group were on dual antiplatelet therapy (ace-
tylsalicylic acid plus P2Y12 inhibitor).
There were also no statistically significant differences in the 
rates of other individual clinical endpoints such as target ves-
sel-related MI (40/692 [5.8%] vs. 40/689 [5.8%], plog-rank=0.98), 
clinically indicated TVR (45/692 [6.5%] vs. 44/689 [6.4%], 
plog-rank=0.84) and cardiac death (13/692 [1.9%] vs. 24/689 [3.5%], 
plog-rank=0.07; Figure 1). The Kaplan-Meier curves of cardiac death 
Table 1. Three-year clinical outcome and outcome difference between one and three years.
Outcome at 3 years Outcome difference between 1 and 3 years
Resolute ZES 
(n=692)
XIENCE V 
EES (n=689)
Difference 
(95% CI)
p-value Resolute
ZES
XIENCE V 
EES
Difference 
(95% CI)
p-value
Target vessel failure 84 (12.1) 92 (13.4) –1.2 (–4.7-2.3) 0.50 4.3 (27/628) 5.7 (36/629) –1.4 (–3.8-1.0) 0.25
Death Any cause 
Cardiac cause
35 (5.1)
13 (1.9)
44 (6.4)
24 (3.5)
–1.3 (–3.8-1.1)
–1.6 (–3.3-0.1)
0.29
0.06
3.0 (20/677)
0.9 (6/677)
4.4 (30/675)
2.1 (14/675)
–1.5 (–3.5-0.5)
–1.2 (–2.5-0.1)
0.15
0.07
Target vessel-related myocardial infarction 40 (5.8) 40 (5.8) 0.0 (–2.5-2.4) 0.98 1.2 (8/646) 1.2 (8/647) 0.0 (–1.2-1.2) 1.00
Clinically indicated target vessel revascularisation 45 (6.5) 44 (6.4) 0.1 (–2.5-2.7) 0.93 3.4 (22/654) 3.8 (25/656) –0.4 (–2.5-1.6) 0.66
Target lesion failure 80 (11.6) 80 (11.6) –0.1 (–3.4-3.3) 0.98 4.0 (25/630) 5.2 (33/638) –1.2 (–3.5-1.1) 0.31
Clinically indicated target lesion revascularisation 37 (5.3) 27 (3.9) 1.4 (–0.8-3.6) 0.21 2.7 (18/658) 2.6 (17/665) 0.2 (–1.6-1.9) 0.84
Major adverse cardiac events 100 (14.5) 99 (14.4) 0.1 (–3.6-3.8) 0.97 6.1 (38/622) 7.7 (48/627) –1.5 (–4.4-1.3) 0.28
Patient-oriented composite endpoint 120 (17.3) 114 (16.5) 0.8 (–3.2-4.8) 0.69 9.0 (55/614) 8.6 (53/616) 0.4 (–2.8-3.5) 0.83
Stent 
thrombosis 
Definite
Definite-or-probable
Very late definite-or-probable*
7 (1.0)
10 (1.4)
4 (0.6)
2 (0.3)
11 (1.6)
3 (0.4)
0.7 (–0.1-1.6)
–0.2 (–1.4-1.1)
0.1 (–0.6-0.9)
0.18
0.82
1.00
0.4 (3/674)
0.6 (4/672)
0.3 (2/675)
0.4 (3/671)
0.1 (–0.5-0.8)
0.1 (–0.6-0.8)
0.69
1.00
Values are % (n/N) or n (%) where appropriate. CI: confidence interval; *definitions of clinical endpoints have previously been reported2
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Figure 1. Kaplan-Meier curves for the composite endpoint target vessel failure (TVF) and its individual components until three-year follow-up. 
(A) TVF, a composite of cardiac death, target vessel-related MI and target vessel revascularisation; (B) cardiac death; (C) target vessel-
related MI; (D) target vessel revascularisation. P-values were derived from the log-rank test; they may differ from p-values reported in the 
manuscript, which were derived from χ2 analysis.
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Figure 2. Cumulative incidence of definite-or-probable stent thrombosis at three-year follow-up. The cumulative incidence of definite-or-
probable stent thrombosis, according to the Academic Research Consortium definition, is shown. DAPT: dual antiplatelet therapy 
(i.e., acetylsalicylic acid plus P2Y12 receptor antagonist)
tended to diverge after one year. We therefore performed post hoc 
a one-year landmark analysis which showed no significant dif-
ference in cardiac death during the first year (7/695 [1.0%] vs. 
10/692 [1.4%], plog-rank=0.46; HR 1.43, 95% CI: 0.55–3.77) and, 
beyond one year, there was only a statistically non-significant 
trend (6/677 [0.9%] vs. 14/675 [2.1%], plog-rank=0.08; HR 2.19, 
95% CI: 0.83–5.77; patients who died during the first year were 
excluded).
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Discussion
Only very limited long-term data of randomised trial populations 
with ≥ three-year follow-up are available for the second-genera-
tion Resolute ZES. The present three-year clinical outcome data 
of the TWENTE trial that were obtained from 1,381 (99.3% of all 
enrolled) patients corroborate the favourable long-term outcome 
in the RESOLUTE All Comers trial, which is the only other ran-
domised DES trial that reported ≥ three-year clinical outcome of 
Resolute ZES1. The observed trend towards a lower cardiac mor-
tality in TWENTE patients treated with Resolute ZES cannot be 
explained by baseline or procedural data. It might be a play of 
chance. Nevertheless, further assessment of clinical follow-up of 
this study population is of interest.
This study was not powered to assess between-group differences 
in secondary clinical endpoints, such as cardiac death. In addi-
tion, our findings may not be generalised to patients with an acute 
ST-elevation MI (first 48 hours), as such patients were not enrolled 
in TWENTE.
Conclusion
The present three-year follow-up of the TWENTE trial demon-
strates a similar and sustained safety and efficacy of the second-
generation Resolute ZES and XIENCE V EES.
Impact on daily practice
The favourable three-year outcome data after use of both per-
manent-polymer drug-eluting stents (DES) in the broad study 
population of the TWENTE randomised trial, which comprised 
a real-world patient population with many patients who had 
complex lesions and various comorbid conditions, are a strong 
signal of sustained safety and efficacy of the compared devices 
in clinical practice. In addition, the consistently low rates of 
adverse clinical events such as stent thrombosis, target ves-
sel-related myocardial infarction and repeat revascularisation, 
which were similar for both DES, represent an important bench-
mark for future comparison with long-term outcome data to be 
obtained after the use of novel DES and biodegradable scaffolds 
in complex patients.
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